The Atrial Flow Regulator device: expanding the field of interatrial shunting for treating heart failure patients
August 29, 2019 | 10.4244/EIJV15I5A73
Showing 1-20 of 21 articles
Interventions for heart failure
Initial Experience with the Second-Generation V-Wave Shunt for Treating Patients with Chronic Heart Failure August 20, 2019 | 10.4244/EIJ-D-19-00291
Interatrial shunting for heart failure: current evidence and future perspectives
June 20, 2019 | 10.4244/EIJ-D-18-01211
Interventions for valvular disease
FORMA Tricuspid Repair System: device enhancements and initial experience March 20, 2019 | 10.4244/EIJ-D-18-00956
Interventions for valvular disease
First-in-man use of the new-generation TriGUARD 3 cerebral embolic protection device during transcatheter aortic valve implantation December 7, 2018 | 10.4244/EIJ-D-18-00442
Early commercial experience from transcatheter aortic valve implantation using the Portico™ bioprosthetic valve: 30-day outcomes in the multicentre PORTICO-1 study
October 19, 2018 | 10.4244/EIJ-D-18-00343
Interventions for valvular disease
To nurture a snake in one’s bosom: aspiration of a giant right atrium thrombus after a MitraClip procedure October 12, 2018 | 10.4244/EIJ-D-18-00411
Interventions for valvular disease
Effect of size and position of self-expanding transcatheter valve on haemodynamics following valve-in-valve procedure in small surgical bioprostheses: an in vitro study June 14, 2018 | 10.4244/EIJ-D-17-00875
Interventions for valvular disease
Combined erythropoietin and iron therapy for anaemic patients undergoing transcatheter aortic valve implantation: the EPICURE randomised clinical trial May 15, 2017 | 10.4244/EIJ-D-16-00591
Interventions for valvular disease
Transcatheter aortic valve replacement with the Portico valve: one-year results of the early Canadian experience January 20, 2017 | 10.4244/EIJ-D-16-00299
Interventions for valvular disease
Transcatheter interventions for tricuspid regurgitation: the FORMA Repair System September 18, 2016 | 10.4244/EIJV12SYA31
Interventions for valvular disease
Thirty-day outcomes in patients at intermediate risk for surgery from the SAPIEN 3 European approval trial June 10, 2016 | 10.4244/EIJV12I2A37
Interventions for valvular disease
Managing heart block after transcatheter aortic valve implantation: from monitoring to device selection and pacemaker indications September 17, 2015 | 10.4244/EIJV11SWA30
Myocardial injury following transcatheter aortic valve implantation: insights from delayed-enhancement cardiovascular magnetic resonance
June 19, 2015 | 10.4244/EIJV11I2A39
Occurrence, fate and consequences of ventricular conduction abnormalities after transcatheter aortic valve implantation
February 20, 2014 | 10.4244/EIJV9I10A194
Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document
November 20, 2012 | 10.4244/EIJV8I7A121
Edwards CENTERA valve
September 30, 2012 | 10.4244/EIJV8SQA14
Edwards SAPIEN 3 valve
September 30, 2012 | 10.4244/EIJV8SQA15